Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience

CONCLUSION: Favorable results can be achived with second-line 177Lu-PSMA-617 treatment in terms of OS and PFS, especially in castration-resistant disease, when chemotherapy and new generation ADT's cannot be used.PMID:38085834 | DOI:10.1967/s002449912603

Source: Hellenic Journal of Nuclear Medicine - December 12, 2023 Category: Nuclear Medicine Authors: Yusuf Zeki Celen Umut Elboga Ertan Sahin Tulay Kus Merve Okuyan Yusuf Burak Cayirli Sakip Erturhan Ufuk Cimen Source Type: research